European Autism GEnomics Registry (EAGER): protocol for a multicentre cohort study and registry
BMJ Open · 2024
DOI: 10.1136/bmjopen-2023-080746 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift BMJ Open, 2024. Verfasst von Madeleine Bloomfield und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Hauptthemen laut MEDLINE: Autistic Disorder, Genomics, Registries, Whole Genome Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation, Innovative Medicines Initiative, HORIZON EUROPE.
Abstract (Originalsprache)
Introduction Autism is a common neurodevelopmental condition with a complex genetic aetiology that includes contributions from monogenic and polygenic factors. Many autistic people have unmet healthcare needs that could be served by genomics-informed research and clinical trials. The primary aim of the European Autism GEnomics Registry (EAGER) is to establish a registry of participants with a diagnosis of autism or an associated rare genetic condition who have undergone whole-genome sequencing. The registry can facilitate recruitment for future clinical trials and research studies, based on genetic, clinical and phenotypic profiles, as well as participant preferences. The secondary aim of EAGER is to investigate the association between mental and physical health characteristics and participants’ genetic profiles. Methods and analysis EAGER is a European multisite cohort study and registry and is part of the AIMS-2-TRIALS consortium. EAGER was developed with input from the AIMS-2-TRIALS Autism Representatives and representatives from the rare genetic conditions community. 1500 participants with a diagnosis of autism or an associated rare genetic condition will be recruited at 13 sites across 8 countries. Participants will be given a blood or saliva sample for whole-genome sequencing and answer a series of online questionnaires. Participants may also consent to the study to access pre-existing clinical data. Participants will be added to the EAGER registry and data will be shared externally through established AIMS-2-TRIALS mechanisms. Ethics and dissemination To date, EAGER has received full ethical approval for 11 out of the 13 sites in the UK (REC 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023), Spain (HCB/2023/0038, PIC-164-22), Sweden (Dnr 2023-06737-01), Ireland (230907) and Italy (CET_62/2023, CEL-IRCCS OASI/24-01-2024/EM01, EM 2024-13/1032 EAGER). Findings will be disseminated via scientific publications and conferences but also beyond to participants and the wider community (eg, the AIMS-2-TRIALS website, stakeholder meetings, newsletters).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
- Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK alexandra.lautarescu@kcl.ac.uk.
- Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, London, UK.
- Department of Psychological Sciences, Birkbeck University of London, London, UK.
- AIMS-2-TRIALS A-Reps, Cambridge University, Cambridge, UK.
- Autism Research Centre, Cambridge University, Cambridge, UK.
ORCID-Profile: Alexandra Lautarescu, Pierre Violland, Miguel Castelo-Branco, Tony Charman
Förderung
- UK Research and Innovation
- Innovative Medicines Initiative
- HORIZON EUROPE
Zitieren
APA
Bloomfield, M., Lautarescu, A., Heraty, S., Douglas, S., Violland, P., Plas, R., Ghosh, A., Van den Bosch, K., Eaton, E., Absoud, M., Battini, R., Blázquez Hinojosa, A., Bolshakova, N., Bölte, S., Bonanni, P., Borg, J., Calderoni, S., Calvo Escalona, R., Castelo-Branco, M., …, & Charman, T. (2024). European Autism GEnomics Registry (EAGER): protocol for a multicentre cohort study and registry. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080746
Vancouver
Bloomfield M, Lautarescu A, Heraty S, Douglas S, Violland P, Plas R, et al. European Autism GEnomics Registry (EAGER): protocol for a multicentre cohort study and registry. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080746
BibTeX
@article{Bloomfield2024,
author = {Bloomfield, Madeleine and Lautarescu, Alexandra and Heraty, Síofra and Douglas, Sarah and Violland, Pierre and Plas, Roderik and Ghosh, Anjuli and Van den Bosch, Katrien and Eaton, Eliza and Absoud, Michael and Battini, Roberta and Blázquez Hinojosa, Ana and Bolshakova, Nadia and Bölte, Sven and Bonanni, Paolo and Borg, Jacqueline and Calderoni, Sara and Calvo Escalona, Rosa and Castelo-Branco, Miguel and Castro-Fornieles, Josefina and Caro, Pilar and Cliquet, Freddy and Danieli, Alberto and Delorme, Richard and Elia, Maurizio and Hempel, Maja and Leblond, Claire S and Madeira, Nuno and McAlonan, Grainne and Milone, Roberta and Molloy, Ciara J and Mouga, Susana and Montiel, Virginia and Pina Rodrigues, Ana and Schaaf, Christian P and Serrano, Mercedes and Tammimies, Kristiina and Tye, Charlotte and Vigevano, Federico and Oliveira, Guiomar and Mazzone, Beatrice and O'Neill, Cara and Pender, Julie and Romero, Verena and Tillmann, Julian and Oakley, Bethany and Murphy, Declan G M and Gallagher, Louise and Bourgeron, Thomas and Chatham, Christopher and Charman, Tony},
title = {European Autism GEnomics Registry (EAGER): protocol for a multicentre cohort study and registry},
journal = {BMJ Open},
year = {2024},
doi = {10.1136/bmjopen-2023-080746}
}
EUVIMED